Predictors of Health Service Utilizations Among Key Population in Washington DC
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Us Helping Us, People Into Living, Inc.
- Study ID
- NCT06046079
- Status
- Recruiting
Conditions
- HIV
- Health Behavior
- Pre-exposure Prophylaxis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
The primary objective of the proposed study is to investigate how PrEP use might result in an increase in the utilization of health and social services offered at a local community-based organization. Our primary hypothesis is that the investigators will observe higher utilization of sexual health (STI screenings), psychosocial health (psychotherapy, and substance use treatment) and other social services (emergency cash assistance, food pantry, transportation assistance, clothing,and housing resources) among PrEP users (LAI-PrEP or daily oral) compared to participants who are PrEP naïve over the 12-month follow-up period.
Key Dates
- First listed
- Sep 21, 2023
- Start date
- Aug 25, 2023
- Status verified
- Mar 2025
- Primary completion
- Jul 3, 2025
- Completion
- Jan 1, 2026
Study Design
- Enrollment
- 100 participants (estimated)
Primary Outcome Measure
The rate of service utilization (sexual health, psychosocial health & other social services) over 12 months as a function of demographic characteristics, mental health, and substance use behavior. [ Time Frame: Over 12 months ]
Central Contacts
- DeMarc Hickson, PhD6786139827
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Us Helping Us, People into Living Inc | Washington D.C. | District of Columbia | 20010 | DeMarc Hickson, PhD |
Find similar trials in Washington D.C., DC
Related Studies
- Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIVRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- The DC Cohort Longitudinal HIV Status Neutral StudyRecruiting · George Washington University · Washington D.C., District of Columbia
- Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-TEnrolling By Invitation · American Gene Technologies International Inc. · Washington D.C., District of Columbia
- Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIVPHASE2 · Recruiting · University of Maryland, Baltimore · Washington D.C., District of Columbia